1. Academic Validation
  2. Prioritizing Neuroactive Ligands Using Motif-Guided Virtual Discovery and Zebrafish Profiling

Prioritizing Neuroactive Ligands Using Motif-Guided Virtual Discovery and Zebrafish Profiling

  • bioRxiv. 2026 Jan 16:2026.01.15.699747. doi: 10.64898/2026.01.15.699747.
Ari B Ginsparg 1 2 Jaqueline A Martinez 2 Ishaan Patel 3 Angélique Buton 4 Laura T Lee 2 Raheel Sarwar 2 Rocco Moretti 5 Stephanie Puig 4 Summer B Thyme 1 2
Affiliations

Affiliations

  • 1 Department of Neurobiology, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama 35294, USA.
  • 2 Department of Biochemistry and Molecular Biotechnology, UMass Chan Medical School, Worcester, Massachusetts 01605, USA.
  • 3 Department of Computational Biology, University of Pennsylvania, Philadelphia, Pennsylvania, 19104.
  • 4 Department of Psychiatry and Behavioral Sciences, UMass Chan Medical School, Worcester, Massachusetts 01605, USA.
  • 5 .Department of Chemistry, Vanderbilt University, Nashville, Tennessee 37240, USA.
Abstract

Virtual screening of ultra-large chemical libraries is a highly effective strategy for early-stage drug discovery. However, these pipelines often yield thousands of molecules that pass computational filters, and in silico-derived interaction energies do not consistently predict experimental efficacy. Furthermore, many high-affinity hits do not necessarily function effectively in an organism with tissues, barriers, and extensive off-target possibilities. A major hurdle in drug discovery is the prioritization of top candidates for rodent testing. Here, we introduce Rosetta Engine for Anchoring Ligands with a Motif ("REAL-M"), a novel computational screening algorithm that uses structural interaction data from the Protein Data Bank (PDB) to guide ligand placement and selection. Using the hypocretin receptor as a test case for this computational pipeline, 28 of 30 predicted antagonists significantly blocked binding of the cognate peptide agonist in a PRESTO-Tango cell-based reporter assay, including six chemically diverse molecules with comparable efficacy to preexisting antagonists. Three of the six molecules significantly mitigated hypocretin-induced larval zebrafish hyperactivity. Secondary testing with a zebrafish hcrtr2 null mutant ensured that behavioral phenotypes were not due to off-target interactions, which we did observe with preexisting antagonists. This pipeline is readily adaptable to the thousands of zebrafish proteins with highly conserved binding pockets.

Figures
Products